RA-10 Reactor Targets 20% of Global Mo-99 Supply, but Gaps Remain

In late 2024, global molybdenum-99 shortages cut supply by up to 50% for several weeks. This disruption triggered patient safety alerts across nuclear medicine systems in Europe and beyond, demonstrating the exact market fragility that the Argentina RA-10 reactor is being commissioned to resolve.

The global isotope market depends entirely on fewer than ten aging reactors, and five of these key facilities are over 50 years old. A single unplanned outage in Belgium or the Netherlands can reverberate across hospital nuclear medicine departments worldwide. This structural vulnerability makes new, purpose-built, geographically diversified capacity a global necessity rather than a regional upgrade.

The Ezeiza-based facility is currently approaching its final commissioning phases with a stated ambition to capture 20% of global supply. With equipment assembly reportedly at 96%, this analysis provides a structured assessment of the variables that will determine if the project achieves commercial relevance by 2027, and where the remaining execution risks sit today.

A 30-megawatt reactor built to fill a gap no incumbent wants to close

The RA-10 is a 30-megawatt thermal capacity open-pool reactor located at the Ezeiza Atomic Centre. It succeeds the legacy RA-3, a 10-megawatt facility that has been operational since 1967. This step-change in output potential shifts the project from a domestic health asset to a deliberate export-oriented commercial play.

While the reactor serves multiple functions, molybdenum-99 export is the primary commercial rationale driving its financial architecture. The facility is designed to support the following secondary operations:

An advanced neutron beam laboratory for scientific research A dedicated facility for the study of irradiated materials Silicon doping capabilities for industrial manufacturing applications Specialised workforce training for the nuclear sector

The projected 20% global supply share positions the RA-10 as a structural contributor to the global outage reserve, rather than a mere margin supplier. The OECD Nuclear Energy Agency (NEA) and the International Atomic Energy Agency (IAEA) noted that in 2016, approximately 95% of global supply came from just seven reactors.

The NEA recommends that the global market maintain an outage reserve capacity of approximately 35% above baseline demand to ensure supply chain resilience.

This capacity specification tells you exactly how the global market operates. Buyers do not need another small contributor; they need a reactor large enough to serve as a credible swing supplier during European outages.

Nuclear technology supply chains share a common vulnerability with the isotope market: geographic concentration of processing capability means a single facility disruption propagates across multiple downstream users simultaneously, amplifying the commercial case for diversified production infrastructure.

Understanding this strategic positioning reframes the entire investment thesis. The commercial case for the RA-10 rests on its role in a structurally undersupplied global market, completely independent of Argentine domestic demand.

Construction progress against a history of delays: what 96% complete actually means

The project timeline reveals a clear pattern of advancement punctuated by systemic delays. The National Atomic Energy Commission (CNEA) launched the initiative in June 2010, and Argentina’s Nuclear Regulatory Authority (ARN) granted a construction licence in November 2014.

Physical works commenced in 2016, but the original four-year construction schedule stretched into a decade-long process. Civil works were eventually completed in early 2024, leading to pre-operational cold tests in May 2025 and the commissioning of the first primary cooling circuit pump in January 2026.

Two figures currently circulate regarding project status: overall progress sits at 85%, while equipment and systems assembly has reached 96%. The gap between these two numbers is analytically meaningful because the final 15% of any nuclear project involves the most difficult hurdles, specifically regulatory approvals and integrated system testing.

The project relies on a workforce of 530 personnel currently on-site, but physical labour cannot accelerate regulatory milestones. Cumulative spending exceeded $400 million by mid-2024, navigating two distinct construction halts in 2019 and September 2024 tied to budget constraints and late payments. Unverified reports suggest a remaining funding shortfall of $80 million.

The six-year schedule overrun tells you that every remaining milestone carries material execution risk. Investors should discount the September target for commissioning and the 2027 commercial operation date accordingly.

What remains between current progress and first criticality

The specific risk standing between current progress and commercial operation is the final operating licence from the ARN. There is no public confirmation that this document has been issued as of September 2026.

Nuclear commissioning and first criticality cannot proceed without this regulatory approval. Unlike engineering delays that management can offset by adding capital, licence issuance follows a fixed assessment process that is inherently non-compressible. Integrated pre-operational testing must conclude flawlessly before the regulator grants approval.

Advanced reactor commissioning timelines consistently exceed initial projections across jurisdictions, a pattern driven by the non-compressible nature of integrated safety testing and regulatory review rather than by construction or engineering failures alone.

How the global Mo-99 market actually works, and where RA-10 fits

The medical isotope market operates differently from almost every other commodity sector. Because molybdenum-99 decays rapidly during transit, global production capacity must structurally exceed actual demand by roughly 50%.

This decay constraint dictates market behaviour. It means the supply chain always requires more installed capacity than hospitals appear to consume on any given day. Supply remains highly concentrated across just a handful of major incumbent reactors, most of which are approaching the end of their operational lifespans:

BR2 (Belgium), operational for over 50 years HFR (Netherlands), operational for over 50 years MARIA (Poland), operational for over 50 years SAFARI-1 (South Africa), operational for over 50 years * OPAL (Australia), operational since 2006

The entire Latin American contribution currently comes from the aging RA-3, which remains marginal relative to global requirements. This geographic concentration creates intense vulnerability.

Commercial estimates value the global market at $5.17 billion in 2025, with projections suggesting a 4.89% compound annual growth rate through 2035. This implies a future market size between $7.74 billion and $8.33 billion. Competing commercial studies report baseline figures ranging from $390 million to $4.14 billion, meaning you must stress-test any market growth thesis against the specific methodology used.

The structural requirement for over-supply reveals the true value of the Argentine project. The RA-10 does not need to displace incumbents to achieve commercial viability; it only needs to provide reliable availability as a reserve supplier.

The 2024 shortage as a proof-of-concept for new entrant value

The supply crisis between August and November of 2024 provides a concrete demonstration of why geographically independent capacity holds a premium. Overlapping shutdowns and delayed restarts at European reactors created a severe supply deficit.

The resulting shortages reduced global supply by up to 50%, prompting immediate patient safety alerts from Nuclear Medicine Europe, the Society of Nuclear Medicine and Molecular Imaging, GE Healthcare, and the UK Parliament.

During this crisis, the RA-3 continued to operate but lacked the scale to offset the European outages. This event illustrated the exact capability gap the RA-10 is designed to fill, proving the market demand for a Latin American alternative.

The financing gap that determines whether 20% market share is a projection or a plan

The Argentine government established a hybrid financing model under Nuclear Activity Law 24.804 to commercialise the reactor’s output. The state retains strategic control and regulatory oversight, but the structure relies on a private partner to build and operate the associated Fission Radioisotope Production Plant (PPRF).

This processing plant is mandatory to convert the reactor’s raw output into market-ready isotopes. The OECD NEA notes that a new processing facility typically requires capital costs exceeding €100 million, while the Argentine model anticipates approximately $200 million in private investment.

Project finance structures for critical supply chain infrastructure increasingly rely on multilateral or government-backed anchor commitments to de-risk private equity participation, a model that the Argentine PPRF financing gap would need to replicate in some form to attract the estimated $200 million required.

As of September 2026, this financing layer remains entirely unconfirmed. There is no publicly named private investor, no signed equity commitment, no project-finance agreement, and no binding offtake contract disclosed (note that these absences remain unverified by independent audit).

Precedent projects show how difficult market entry can be. SHINE Medical Technologies in the United States found that novel facilities require extensive pre-commercial testing, reportedly sustaining accelerator performance at 95% uptime over 132-hour runs to de-risk operations. South Africa’s NTP faced logistical complications and increased radioactive waste volumes during its transition, while Australia’s OPAL encountered strict environmental limits on waste storage.

Furthermore, the NEA and IAEA report that the historical economic unsustainability of the isotope market often causes developers to underestimate industrialisation timelines. Argentina’s macroeconomic context, including currency volatility and prior budget constraints, compounds this risk.

Without a confirmed private partner, the projected 20% market share is a physical capacity claim rather than a commercial reality. The reactor can produce irradiated targets, but you cannot model export revenue until the PPRF capital is committed.

To evaluate this project accurately, you must track three specific risk categories in descending order of materiality:

1. Confirmation of private financing for the PPRF processing plant
2. Issuance of the final ARN operating licence
3. Market penetration against incumbent distribution networks

What the evidence actually resolves, and what it does not

Physical construction of the reactor is effectively complete, and the 30-megawatt capacity is undeniably sufficient to achieve a material share of global supply. The structural market need is real, and the hybrid financing model is legally viable under Argentine law.

However, the evidence does not yet support the July 2027 commercial operation target. That timeline is contingent on three unresolved variables, each independently capable of causing significant delays.

The current situation gives you a precise monitoring checklist. If all three of these variables are resolved by mid-2027, the long-term investment thesis strengthens materially:

1. ARN operating licence: Confirmed only when the regulator publicly issues the final operating document, which is entirely distinct from the construction licence granted in 2014.
2. PPRF private partner: Confirmed when a specific corporate entity formally commits the estimated $200 million required for the processing plant.
3. Offtake agreements: Confirmed when binding distribution contracts are publicly announced, proving market penetration against incumbent networks.

Supply agreement frameworks for molybdenum-based materials demonstrate how buyers structure long-term procurement commitments when facing concentrated supplier risk, a precedent that informs how hospital networks and radiopharmacy distributors might approach offtake negotiations with a new entrant like the RA-10.

If any one of these factors remains open, the 2027 commercial timeline should be treated as unreliable. The facility remains a credible long-term play on supply diversification, but the near-term milestones carry execution risk that is incompatible with a firm commercial commitment.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions. Past performance does not guarantee future results. Financial projections are subject to market conditions and various risk factors.